Clinical Trials

New Clinical Trial in the Works to Test Important Combination Therapy

Dear Friends at CLL Topics: 

Berlex has decided to close the study FluCam 106, “A Phase II Study Comparing Fludarabine/Campath to Fludarabine/Rituximab.” This decision was reached as a result of low enrollment on the current study and strong feedback that indicated that the scientific question asked continues to be of interest. Comments from many of the investigators indicated that the stringent  inclusion / exclusion criteria, rigorous schedule of events and overall protocol complexity made it difficult to enroll patients. Therefore, based on this feedback, we will be developing a new study which asks a similar scientific question, however the overall complexity of the study design will be greatly reduced - a benefit to both the investigator and the patient. Berlex will continue to keep CLL Topics apprised of the progress on this new study and the sites that will be participating.  We expect the new trial to be up and running by March of 2024. 

Best regards,

Andrew S. Sandler, M.D.
Associate Director
Berlex Oncology

Details of the FluCam 106 clinical trial as originally constituted are provided in our article titled FluCam 106.